During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Steven Treon from Dana-Farber Cancer Institute, Boston, US, about the long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib.
Steven Treon discusses the long-term follow-up of a multi-institutional trial investigating ibrutinib, which is highly active in patients with Waldenstrom's macroglobulinemia.